Wassil Nowicky
Phd, Ukrainian Anti-Cancer Institute
Title: Effect of the anti-cancer preparation NSCâ€631570 (Ukrain) in pancreatic carcinoma
Biography
Biography: Wassil Nowicky
Abstract
In a controlled randomised study by Prof. Beger et al. in the Ulm University Hospital, Germany, the therapy with NSCâ€631570 and gemcitabine doubled the survival rate in the patients with inoperable advanced pancreatic cancer [http://www.ncbi.nlm.nih.gov/pubmed/11914932 ]. The longest survival was 19 months in the group treated with gemcitabine alone, 26 months in the combined group, and in the NSCâ€631570 alone group two patients were alive after 28 months. NSCâ€631570 was well tolerated. The study authors consider further evaluation of NSCâ€631570 as justified whereas the quality of life of the patients improved [[1]].
Patients were further observed after the conclusion of the study and it was noted that UKRAIN was well tolerated and could be administered without problem to all patients. UKRAIN brought about a significant increase in survival time in comparison to therapy with gemcitabine alone. Combination therapy with gemcitabine and UKRAIN showed no advantage over monotherapy with UKRAIN. The longest survival in the gemcitabine group was 19 months, 21 months in the gemcitabine+Ukrain group, and in the Ukrain group a patient was still alive after 28 months. The authors concluded: “As a result of this study we highly recommend the treatment of patients suffering from advanced pancreatic cancer with Ukrain” [[2]].
2007 the results of another clinical study by the same research team were published. This time the efficacy of the adjuvant therapy with NSCâ€631570 has been demonstrated in the patients with advanced pancreatic cancer after surgery. The patients were treated with a combination of NSCâ€631570 and gemcitabine.
[1] Gansauge F, Ramadani M, Beger HG (2002): Ukrain beim fortgeschrittenen Pankreaskarzinom. Ars Medici, 22:1056â€1062.
[2] Gansauge F (2002): Ukrain in Pancreatic cancer: Study Final Report. In. University Ulm.